Galiano Gold Q3 2026 Net Income Swings to USD 40.51 Million Profit Year Over Year
Bitget2026/11/05 23:30- Galiano Gold swung to third-quarter 2026 net income attributable to common shareholders of USD 40.51 million from a year-earlier loss.
- Revenue climbed 51% year over year to USD 172.14 million, driven by higher gold sales volumes and prices.
- Cash flow from operating activities rose 41% from a year earlier to USD 56.95 million.
- Gold production increased 19% quarter over quarter to 40,922 ounces.
- Full-year 2026 production guidance remained unchanged at 140,000 to 160,000 ounces.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Crypto prices
More
